XTX Topco Ltd Has $730,000 Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

XTX Topco Ltd lifted its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 1,581.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 178,465 shares of the company’s stock after purchasing an additional 167,854 shares during the period. XTX Topco Ltd owned 0.25% of Zentalis Pharmaceuticals worth $730,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. ProShare Advisors LLC lifted its stake in shares of Zentalis Pharmaceuticals by 9.0% in the 1st quarter. ProShare Advisors LLC now owns 15,436 shares of the company’s stock valued at $243,000 after purchasing an additional 1,274 shares during the last quarter. Quest Partners LLC acquired a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter valued at $38,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Zentalis Pharmaceuticals by 0.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 445,823 shares of the company’s stock valued at $6,754,000 after purchasing an additional 3,759 shares during the last quarter. Values First Advisors Inc. lifted its stake in shares of Zentalis Pharmaceuticals by 5.4% in the 2nd quarter. Values First Advisors Inc. now owns 74,925 shares of the company’s stock valued at $306,000 after purchasing an additional 3,859 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Zentalis Pharmaceuticals by 66.5% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 13,634 shares of the company’s stock valued at $215,000 after purchasing an additional 5,446 shares during the last quarter.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL opened at $4.22 on Monday. The company has a 50-day simple moving average of $3.56 and a 200-day simple moving average of $8.32. The firm has a market capitalization of $299.73 million, a P/E ratio of -1.27 and a beta of 1.70. Zentalis Pharmaceuticals, Inc. has a 52 week low of $2.83 and a 52 week high of $22.70.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Friday, August 9th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.40). During the same quarter in the prior year, the business posted ($1.85) EPS. As a group, equities analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

ZNTL has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Monday, August 12th. Wells Fargo & Company lowered Zentalis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $29.00 to $9.00 in a report on Tuesday, June 18th. Stifel Nicolaus dropped their price target on Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, June 18th. UBS Group cut Zentalis Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $28.00 to $5.00 in a research report on Thursday, June 20th. Finally, Wedbush raised shares of Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 target price on the stock in a research report on Monday, August 12th. Seven analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $10.78.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.